Zika Virus

Zika virus is a member of the virus family Flaviviridae and the genus Flavivirus, transmitted by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus

What is the Zika virus?

The Zika virus causes fever, joint pain, headaches, a rash, conjunctivitis and muscle pain. As with other viruses, it is characterised by spreading via the cells of the body. Both men and women can contract the disease. It is a member of the Flavivirus genus which is a member of the Flaviviridae family.

Zika diagnosis

Zika prevention

Zika symptoms

Zika transmission

Zika treatment

Zika vaccine development

Zika virus in pregnant women

Zika Virus Research

Zika Virus History

Zika and Guillain-Barré Syndrome

What can Aedes mosquitoes transmit?

Latest Zika Virus News and Research

T cells can counteract dangerous phenomenon of mosquito-borne viruses

Every year, more than 68,000 people end up with a clinical case of Japanese encephalitis. One in four of these patients will die. The mosquito-borne virus, which is most common in Southeast Asia, also causes severe neurological damage and psychiatric disorders.

5 Jun 2020

Researchers analyze data on RNA structure of tick-borne encephalitis virus

Researchers from Sechenov University together with colleagues from several Russian institutes analyzed data on the RNA structure of tick-borne encephalitis virus.

22 May 2020

COVID-19 may damage the central nervous system

Researchers at University Hospital Düsseldorf, Germany, have provided important insights into the potential impact that coronavirus disease 2019 (COVID-19) could have on the central nervous system.

21 May 2020

Researchers highlight the need to revise the protocol for detecting ZIKV infection in placenta

Shortly after the explosion in microcephaly cases caused by Zika virus in Brazil in 2015-16, several scientific studies were published with evidence that the pathogen is capable of crossing the human placenta, the organ that keeps the fetus connected to the mother's body during pregnancy.

20 May 2020

Main receptors used by SARS-CoV-2 for cell entry are absent in the human placenta

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unlikely to infect human placenta through the canonical cell entry mediators, Wayne State University researchers showed that other interacting proteins may still play an important role during the viral infection. The study is currently available on the preprint server bioRxiv.

20 May 2020

Prellis Externalized Human Immune System produces human antibodies against SARS-Cov2

Prellis Biologics, Inc. today announced that it has generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.

20 May 2020

SMART researchers awarded NMRC funding to develop rapid paper-based COVID-19 tests

Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, has received a grant from the National Medical Research Council COVID-19 Research fund for the acceleration of research and development of rapid paper-based serological and diagnostic tests for COVID-19.

18 May 2020

Developing a COVID-19 antigen test

News-Medical speaks to Alastair Smith, the CEO of Avacta, about the process behind their newly developed antigen test for COVID-19.

From Avacta Life Sciences Ltd. 15 May 2020

Portable, reusable coronavirus sensor produces results within a minute

"Testing, testing, testing." It's a mantra that health officials have been constantly promoting because screening people for COVID-19 is the best way to contain its spread. In the U.S., however, that crucial necessity has been hampered due to a lack of supplies.

7 May 2020

New mathematical tool can predict the spread of infectious diseases more accurately

An international team of researchers has developed a new mathematical tool that could help scientists to deliver more accurate predictions of how diseases, including COVID-19, spread through towns and cities around the world.

5 May 2020

Study sheds new light on the body's initial response to DENV infection

A study led by scientists at the Walter Reed Army Institute of Research sheds new light on the body's initial response to dengue virus (DENV) infection, describing the molecular diversity and specificity of the antibody response.

4 May 2020

Newly launched clinical trial can help treat COVID-19 patients

Research by University of Iowa virologist Wendy Maury, PhD, has helped facilitate the launch of a new clinical trial in the United Kingdom of a drug that might help treat patients with COVID-19.

30 Apr 2020

GlobalData offers view on Gilead’s suspension of Covid-19 trials in China

Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus have been suspended due to lack of eligible patients;

From Gilead Sciences, Inc. 29 Apr 2020

Disarmed anthrax toxin tested as a way to combat Covid-19

Disarmed anthrax toxin is being tested as a way of fighting the Covid-19 virus.

28 Apr 2020

Research provides insights into how Zika virus can spread through sexual contact

Zika virus is capable of replicating and spreading infectious particles within the outermost cells lining the vaginal tract, according to new research. The findings provide the first molecular-level insights into how the virus can move from person to person through sexual contact.

27 Apr 2020

Misinformation on COVID-19 is tied to media usage

People who relied on conservative media or social media in the early days of the COVID-19 outbreak were more likely to be misinformed about how to prevent the virus and believe conspiracy theories about it, a study of media use and public knowledge has found.

25 Apr 2020

Stuttering DNA controls development of mosquito embryos

All organisms have DNA, the genetic material that provides a blueprint for life. The long double-helix-shaped DNA molecules in the body's cells are first translated into RNA molecules and then translated into proteins that ensure the functioning of the cell and the entire organism.

12 Apr 2020

Avacta partners with Cytiva to develop a rapid test for COVID-19

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences.

From Avacta Life Sciences Ltd. 9 Apr 2020

Antiparasitic drug Ivermectin kills coronavirus in 48 hours

Around the world, scientists race to develop a vaccine or treatment against the coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Now, a team of researchers has found that a drug already available around the world can kill the coronavirus in a lab setting in just 48 hours.

6 Apr 2020

Australian scientists identify possible coronavirus drug

A collaborative study led by Monash University's Biomedicine Discovery Institute in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity, has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.

3 Apr 2020